logo
welcome
ABC News

ABC News

UK regulator approves second Alzheimer's drug in months but government won't pay for it

ABC News
Summary
Nutrition label

88% Informative

UK regulator approves second Alzheimer's drug in months but government won't pay for it.

Independent watchdog agency said the treatment isn't worth the cost to taxpayers.

Kisunla, also known as donanemab, works by removing a sticky protein from the brain believed to cause Alzheimer’s disease.

In August , the U.K. regulator authorized the drug while the same watchdog agency issued draft guidance recommending against its purchase for the National Health Service .